Current concepts in the management of Helicobacter pylori infection:: the maastricht III consensus report

被引:1423
作者
Malfertheiner, P.
Megraud, F.
O'Morain, C.
Bazzoli, F.
El-Omar, E.
Graham, D.
Hunt, R.
Rokkas, T.
Vakil, N.
Kuipers, E. J.
机构
[1] Univ Magdeburg, Fak Med, Zentrum Innere Med, Klin Gastroenterol Hepatol & Infektiol, D-39120 Magdeburg, Germany
[2] INSERM, U853, Bordeaux, France
[3] Univ Dublin Trinity Coll, Adelaide & Meath Hosp, Dublin, Ireland
[4] Univ Bologna, Bologna, Italy
[5] Univ Aberdeen, Aberdeen AB9 1FX, Scotland
[6] VA Med Ctr, Houston, TX USA
[7] McMaster Univ, Hamilton, ON, Canada
[8] Henry Dunant Hosp, Athens, Greece
[9] Univ Wisconsin, Sch Med, Milwaukee, WI 53201 USA
[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
关键词
D O I
10.1136/gut.2006.101634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat'' strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naive users of non-steroidal antiinflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
引用
收藏
页码:772 / 781
页数:10
相关论文
共 100 条
[1]   Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis [J].
Annibale, B ;
Marignani, M ;
Monarca, B ;
Antonelli, G ;
Marcheggiano, A ;
Martino, G ;
Mandelli, F ;
Caprilli, R ;
Delle Fave, G .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :668-672
[2]  
[Anonymous], 2003, CAN J GASTROENTER SB
[3]   Stomach cancer and occupation in Sweden:: 1971-89 [J].
Aragonés, N ;
Pollán, M ;
Gustavsson, P .
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2002, 59 (05) :329-337
[4]   Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study [J].
Asaka, M ;
Sugiyama, T ;
Nobuta, A ;
Kato, M ;
Takeda, H ;
Graham, DY .
HELICOBACTER, 2001, 6 (04) :294-299
[5]   Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection [J].
Bilardi, C ;
Biagini, R ;
Dulbecco, P ;
Iiritano, E ;
Gambaro, C ;
Mele, MR ;
Borro, P ;
Tessieri, L ;
Zentilin, P ;
Mansi, C ;
Vigneri, S ;
Savarino, V .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) :1733-1738
[6]  
Bravo LE, 1999, AM J GASTROENTEROL, V94, P2380, DOI 10.1111/j.1572-0241.1999.01361.x
[7]  
Breuer T, 1999, AM J GASTROENTEROL, V94, P725, DOI 10.1111/j.1572-0241.1999.00943.x
[8]   CANCER RISK FOLLOWING PERNICIOUS-ANEMIA [J].
BRINTON, LA ;
GRIDLEY, G ;
HRUBEC, Z ;
HOOVER, R ;
FRAUMENI, JF .
BRITISH JOURNAL OF CANCER, 1989, 59 (05) :810-813
[9]   What is the optimal length of proton pump inhibitor-based triple therapies for H-pylori?: A cost-effectiveness analysis [J].
Calvet, X ;
Gené, E ;
López, T ;
Gisbert, JP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (07) :1067-1076
[10]   Variation in antibiotic use in the European Union [J].
Cars, O ;
Mölstad, S ;
Melander, A .
LANCET, 2001, 357 (9271) :1851-1853